Related Experiment Video
Updated: Aug 31, 2025
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
534
Anti-SOX1 Antibody-positive Small-cell Lung Cancer That Triggered Opsoclonus
Yuki Chiko1, Yuka Sugisaki1, Keiji Miyoshi2
1Department of Internal Medicine, Independent Administrative Agency, National Hospital Organization, Fukuyama Medical Center, Japan.
Internal Medicine (Tokyo, Japan)
|August 21, 2022
Summary
This case report details a patient with small-cell lung cancer and paraneoplastic opsoclonus-myoclonus syndrome. The presence of anti-SOX1 antibodies, a novel finding, correlated with symptom improvement after treatment.
Area of Science:
- Neurology
- Oncology
- Immunology
Background:
- Paraneoplastic opsoclonus-myoclonus syndrome (OMS) is a rare autoimmune disorder often associated with underlying malignancy.
- Opsoclonus, characterized by involuntary, rapid, conjugate eye movements, can significantly impact patient quality of life.
Observation:
- A 72-year-old woman presented with opsoclonus and was diagnosed with small-cell lung cancer.
- Blood tests identified anti-SOX1 antibodies, leading to a diagnosis of paraneoplastic OMS.
Findings:
- This is the first reported case of paraneoplastic OMS associated with anti-SOX1 antibodies.
- The patient experienced improvement in opsoclonus following steroid pulse therapy and chemotherapy.
Implications:
- The findings suggest that anti-SOX1 antibodies may be a potential biomarker for paraneoplastic OMS in small-cell lung cancer patients.
- This case expands the known autoantibody profile associated with paraneoplastic OMS, highlighting the importance of comprehensive antibody testing in diagnosis and management.
